In this review:
Exploratory spatial biomarkers in primary prostate cancer
Reducing BCG toxicity via sensory pathways
Aspartate metabolism in castration/enzalutamide-resistant prostate cancer
ctDNA testing in metastatic prostate cancer
Complex treatment decision-making in genitourinary oncology
The growing financial burden of cancer care
Lu-PSMA, the TME & prostate cancer cell differentiation
The Plasmalogen Score in metastatic prostate cancer
Drivers of progression in aggressive prostate cancer
PSMA-PET in low- to favourable-intermediate-risk prostate cancer
Cxbladder Triage Plus for suspected urothelial carcinoma
Please login below to download this issue (PDF)